INSERM: Core activities within CARAT

The French National Institute of Health and Medical Research (INSERM) will be involved in CARAT via the Cochin Institute, one of its most important research centres. INSERM is a public scientific and technological institute which operates under the joint authority of the French Ministry of Health and French Ministry of Research. The Cochin Institute, founded in 2002, is located on the campus of the Cochin Hospital, one of the most active Hospitals downtown Paris. Its focus is on the study of human pathologies in various domains: cancer, genetics, metabolic diseases, autoimmunity doing basic research as well as translational research particularly in ‘Oncology’. The Institute is organized in three thematic units:

  • Endocrinology, metabolism and Diabetes (EMD)
  • Development, Reproduction and Cancer (DRC)
  • Infection, Immunity and Inflammation (3I)

A major strength of the Cochin Institute is the establishment and regular implementation of state-of-the-art core facilities, committed to provide extensive analysis of biological materials using advanced technologies. The Institute runs 9 individual research facilities, including the ‘Cellular Imaging facility’ which is involved in CARAT.

As Work Package Leader of WP4, INSERM leads the activities with regard to “Monitoring and Mapping technologies”. The group among Emmanuel Donnadieu has developed an innovative approach of tissue slices which, combined with dynamic imaging technology, permits the monitoring of various cells including lymphocytes in fresh tissues. Originally set up in the mouse, this approach was successively transposed to human lung tumours obtained through fruitful collaborations with clinicians from Cochin Hospital.

Our goal in CARAT is to implement and use such techniques to investigate, in a preserved tumor microenvironment, the efficacy of CAR T-cells produced by other members of the CARAT consortium.

Inserm 1 2 3
INSERM Profile

Question & Answers from the INSERM Team

Chahrazade kantari
Chahrazade Kantari-Mimoun
Post-doctoral fellow
I am very excited to be part of this collaborative European research network. By setting up this preclinical monitoring approach, we are at the interface between colleagues who develop innovative CAR T-cells and clinicians ready to launch clinical trials. This gives me the unique opportunity to interact with many partners from academia, the private sector and the clinic.
Emmanuel donnadieu
Emmanuel Donnadieu
Team leader
Cancer immunotherapies including the CAR T strategy are making the headlines these days. This is due to very promising results obtained in a number of malignancies. One of the challenges ahead is to render these therapeutic interventions even more effective as a still large number of cancer patients is refractory to these treatments. This is one of the goals of the CARAT consortium.
Sarah barrin
Sarah Barrin
I am very excited to be able to work together with people with great knowledge in immunology and oncology fields and to gather together all the different expertise we have. This will enable us to make CAR T-cells work in solid tumors and create a new strategy to treat cancer patients.